The US FDA has approved aflibercept-boav, a vascular endothelial growth factor (VEGF) inhibitor biosimilar indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Clinical evidence In clinical trials involving 348 patients with diabetic macular edema, the aflibercept-boav biosimilar demonstrated equivalent efficacy, safety, and immunogenicity to the reference product.
Dosage and administration Available in intravitreal injection form Neovascular (Wet) Age-Related Macular Degeneration (AMD)- The recommended dose for aflibercept-boav is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal…
